Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial

Nirav N. Shah,Bryon D. Johnson,Dina Schneider,Fenlu Zhu,Aniko Szabo,Carolyn A. Keever-Taylor,Winfried Krueger,Andrew A. Worden,Michael J. Kadan,Sharon Yim,Ashley Cunningham,Mehdi Hamadani,Timothy S. Fenske,Boro Dropulić,Rimas Orentas,Parameswaran Hari

DOI: https://doi.org/10.1038/s41591-020-1081-3

IF: 82.9

2020-10-01

Nature Medicine

Abstract:Chimeric antigen receptor (CAR) T cells targeting CD19 are a breakthrough treatment for relapsed, refractory B cell malignancies^{<a href="#ref-CR1">1</a>,<a href="#ref-CR2">2</a>,<a href="#ref-CR3">3</a>,<a href="#ref-CR4">4</a>,<a href="/articles/s41591-020-1081-3#ref-CR5">5</a>}. Despite impressive outcomes, relapse with CD19⁻ disease remains a challenge. We address this limitation through a first-in-human trial of bispecific anti-CD20, anti-CD19 (LV20.19) CAR T cells for relapsed, refractory B cell malignancies. Adult patients with B cell non-Hodgkin lymphoma or chronic lymphocytic leukemia were treated on a phase 1 dose escalation and expansion trial (<a href="https://clinicaltrials.gov/ct2/show/NCT03019055?term=NCT03019055&amp;draw=2&amp;rank=1">NCT03019055</a>) to evaluate the safety of 4-1BB–CD3ζ LV20.19 CAR T cells and the feasibility of on-site manufacturing using the CliniMACS Prodigy system. CAR T cell doses ranged from 2.5 × 10⁵–2.5 × 10⁶ cells per kg. Cell manufacturing was set at 14 d with the goal of infusing non-cryopreserved LV20.19 CAR T cells. The target dose of LV20.19 CAR T cells was met in all CAR-naive patients, and 22 patients received LV20.19 CAR T cells on protocol. In the absence of dose-limiting toxicity, a dose of 2.5 × 10⁶ cells per kg was chosen for expansion. Grade 3–4 cytokine release syndrome occurred in one (5%) patient, and grade 3–4 neurotoxicity occurred in three (14%) patients. Eighteen (82%) patients achieved an overall response at day 28, 14 (64%) had a complete response, and 4 (18%) had a partial response. The overall response rate to the dose of 2.5 × 10⁶ cells per kg with non-cryopreserved infusion (<i>n</i> = 12) was 100% (complete response, 92%; partial response, 8%). Notably, loss of the CD19 antigen was not seen in patients who relapsed or experienced treatment failure. In conclusion, on-site manufacturing and infusion of non-cryopreserved LV20.19 CAR T cells were feasible and therapeutically safe, showing low toxicity and high efficacy. Bispecific CARs may improve clinical responses by mitigating target antigen downregulation as a mechanism of relapse.

biochemistry & molecular biology,cell biology,medicine, research & experimental